Alkermes Shares Rise After ALKS 7290 Shows Positive Phase 1b Results in ADHD

Alkermes plc (ALKS) reported positive topline results on Sept. 21, 2026, from a Phase 1b proof-of-concept trial of ALKS 7290 in adults with attention-deficit hyperactivity disorder (ADHD), sending the company's stock higher. The study evaluated the investigational therapy's tolerability and early efficacy signals in adult ADHD patients, the company said. Alkermes did not disclose detailed efficacy figures or the number of participants in the release. The company said the data support further clinical development of ALKS 7290.